Drug Profile
Research programme: therapeutic monoclonal antibodies - Pyxis Oncology/Janssen Biotech
Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Apexigen; Centocor Ortho Biotech
- Developer Janssen Biotech; Pyxis Oncology
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 20 Mar 2014 Early research is ongoing in USA